Cat. No.: HY-12109

Copy Link Print Information

L-870810

L-870810 is a potent HIV-1 IN chain transfer inhibitor with antiviral activity.

For research use only. We do not sell to patients.

CAS No.: 410544-95-5
Formula: C₂₀H₁₉FN₄O₄S
Molecular Weight:430.45

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (268 KB)

L-870810 Chemical Structure

CAS No.: 410544-95-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

L-870810 is a potent HIV-1 IN chain transfer inhibitor with antiviral activity^[1].

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
C8166	CC₅₀	132 μM Compound: I-4, L-870810	Toxicity against human C8166 cells incubated for 72 hrs by MTT assay Toxicity against human C8166 cells incubated for 72 hrs by MTT assay	[PMID: 23098137]
C8166	EC₅₀	5 nM Compound: I-4, L-870810	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in virus-induced cytopathogenicity measured after 3 days by syncytium reduction assay Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in virus-induced cytopathogenicity measured after 3 days by syncytium reduction assay	[PMID: 23098137]
C8166	CC₅₀	123 μM Compound: L-870810	Cytotoxicity against human C8166 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human C8166 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27810592]
C8166	EC₅₀	2.33 nM Compound: L-870810	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	[PMID: 27810592]
HCT-116	IC₅₀	2 μM Compound: I-4, L-870810	Cytotoxicity against p53 deficient human HCT116 cells incubated for 72 hrs by MTT assay Cytotoxicity against p53 deficient human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 23098137]
HCT-116	IC₅₀	2 μM Compound: I-4, L-870810	Cytotoxicity against p53 expressing human HCT116 cells incubated for 72 hrs by MTT assay Cytotoxicity against p53 expressing human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 23098137]
Lymphocyte	CC₅₀	2100 nM Compound: L-870810	Cytotoxicity against human T lymphocyte cells infected with HIV1 BAL by XTT method in presence of 10% FBS Cytotoxicity against human T lymphocyte cells infected with HIV1 BAL by XTT method in presence of 10% FBS	[PMID: 19104010]
Lymphocyte	EC₅₀	3 nM Compound: L-870810	Antiviral activity against 0.001 MOI HIV1 BAL infected in human T lymphocyte cells by p24 antigen ELISA in presence of 10% FBS Antiviral activity against 0.001 MOI HIV1 BAL infected in human T lymphocyte cells by p24 antigen ELISA in presence of 10% FBS	[PMID: 19104010]
Lymphocyte	EC₅₀	60 nM Compound: L-870810	Antiviral activity against 0.001 MOI HIV1 BAL infected in human T lymphocyte cells by p24 antigen ELISA in presence of 10% FBS, HSA and alpha1-AGP Antiviral activity against 0.001 MOI HIV1 BAL infected in human T lymphocyte cells by p24 antigen ELISA in presence of 10% FBS, HSA and alpha1-AGP	[PMID: 19104010]
MCF7	IC₅₀	2 μM Compound: I-4, L-870810	Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 23098137]
MDA-MB-435	IC₅₀	6 μM Compound: I-4, L-870810	Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay	[PMID: 23098137]
MT2	EC₅₀	0.0038 μM Compound: 1, L-870810	Antiviral activity against HIV1 3B in MT2 cells Antiviral activity against HIV1 3B in MT2 cells	[PMID: 16723225]
MT2	EC₅₀	0.088 μM Compound: 1, L-870810	Antiviral activity against HIV1 3B assessed as protein binding effect in MT2 cells Antiviral activity against HIV1 3B assessed as protein binding effect in MT2 cells	[PMID: 16723225]
MT2	EC₅₀	2 nM Compound: L-870810	Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS	[PMID: 19104010]
MT2	EC₅₀	200 nM Compound: L-870810	Antiviral activity against 0.04 MOI HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 100% human serum Antiviral activity against 0.04 MOI HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 100% human serum	[PMID: 19104010]
MT2	EC₅₀	41 nM Compound: L-870810	Antiviral activity against 0.01 MOI HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 100% human serum Antiviral activity against 0.01 MOI HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 100% human serum	[PMID: 19104010]
MT2	EC₅₀	43 nM Compound: L-870810	Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS, HSA and alpha1-AGP Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS, HSA and alpha1-AGP	[PMID: 19104010]
MT2	EC₅₀	96 nM Compound: L-870810	Antiviral activity against 0.02 MOI HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 100% human serum Antiviral activity against 0.02 MOI HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 100% human serum	[PMID: 19104010]
MT2	CC₅₀	3 μM Compound: L-870810	Cytotoxicity against human MT2 cells infected with HIV1 3B by three fold dilution method in presence of 10% FBS Cytotoxicity against human MT2 cells infected with HIV1 3B by three fold dilution method in presence of 10% FBS	[PMID: 19104010]
MT4	CC₅₀	2.15 μM Compound: 1 (Page 7085)	Cytotoxic concentration required to reduce MT-4 cell viability Cytotoxic concentration required to reduce MT-4 cell viability	[PMID: 16250669]
MT4	EC₅₀	0.0047 μM Compound: 1 (Page 7085)	Effective concentration required to reduce HIV-1-induced cytopathic effect in MT-4 cells Effective concentration required to reduce HIV-1-induced cytopathic effect in MT-4 cells	[PMID: 16250669]
MT4	EC₅₀	3.6 nM Compound: 5, L-870810	Antiviral activity against HIV1 3b in human MT4 cells Antiviral activity against HIV1 3b in human MT4 cells	[PMID: 16509568]
MT4	CC₅₀	1.5 μM Compound: 1, L-870810	Cytotoxicity against MT4 cells Cytotoxicity against MT4 cells	[PMID: 16723225]
MT4	EC₅₀	11 nM Compound: L-870810	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT-4 cells assessed as inhibition of viral replication Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT-4 cells assessed as inhibition of viral replication	[PMID: 18160521]
MT4	EC₅₀	2.2 nM Compound: L-870810	Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus infected in human MT-4 cells assessed as inhibition of viral replication Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus infected in human MT-4 cells assessed as inhibition of viral replication	[PMID: 18160521]
MT4	CC₅₀	2.2 μM Compound: L-870810	Cytotoxicity against human MT4 cells by MTT method Cytotoxicity against human MT4 cells by MTT method	[PMID: 18351727]
MT4	EC₅₀	0.0047 μM Compound: L-870810	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay	[PMID: 18351727]
MT4	EC₅₀	0.004 μM Compound: L-870810	Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.004 μM Compound: L-870810	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.005 μM Compound: L-870810	Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.007 μM Compound: L-870810	Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.018 μM Compound: L-870810	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.064 μM Compound: L-870810	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.073 μM Compound: L-870810	Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.11 μM Compound: L-870810	Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.17 μM Compound: L-870810	Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.19 μM Compound: L-870810	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.55 μM Compound: L-870810	Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound	[PMID: 18378713]
MT4	IC₅₀	1.1 μM Compound: L-870810	Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 50 passages in presence of compound Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 50 passages in presence of compound	[PMID: 18378713]
MT4	CC₅₀	2.25 μM Compound: L-870810	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.0049 μM Compound: L-870810	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of viral replication Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of viral replication	[PMID: 18541726]
MT4	CC₅₀	1600 nM Compound: L-870810	Cytotoxicity against human MT4 cells infected with HIV1 3B by three fold dilution method in presence of 10% FBS Cytotoxicity against human MT4 cells infected with HIV1 3B by three fold dilution method in presence of 10% FBS	[PMID: 19104010]
MT4	EC₅₀	4 nM Compound: L-870810	Antiviral activity against HIV1 3B infected in human MT-4 cells by two fold dilution method in presence of 10% FBS Antiviral activity against HIV1 3B infected in human MT-4 cells by two fold dilution method in presence of 10% FBS	[PMID: 19104010]
MT4	EC₅₀	2 nM Compound: 70; L-870810	Antiviral activity against HIV infected in human MT4 cells assessed as suppression of viral replication Antiviral activity against HIV infected in human MT4 cells assessed as suppression of viral replication	[PMID: 26509831]
SK-N-MC	IC₅₀	28 μM Compound: 5, L-870810	Inhibition of CGRP receptor in human SK-N-MC cells assessed as inhibition of CGRP-stimulated cAMP production after 1 hr Inhibition of CGRP receptor in human SK-N-MC cells assessed as inhibition of CGRP-stimulated cAMP production after 1 hr	[PMID: 21982500]
SUP-T1	CC₅₀	1900 nM Compound: L-870810	Cytotoxicity against human SupT1 cells infected with HIV1 3B Cytotoxicity against human SupT1 cells infected with HIV1 3B	[PMID: 19104010]
SUP-T1	EC₅₀	1.3 nM Compound: L-870810	Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of integrated junction products after 48 hrs by Alu-PCR assay Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of integrated junction products after 48 hrs by Alu-PCR assay	[PMID: 19104010]
SUP-T1	EC₅₀	>1000 nM Compound: L-870810	Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of late RT products after 12 hrs Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of late RT products after 12 hrs	[PMID: 19104010]

Chemical Information

CAS No. 410544-95-5
Molecular Weight 430.45
Formula C₂₀H₁₉FN₄O₄S
SMILES

O=C(C1=NC(N(CCCC2)S2(=O)=O)=C3C=CC=NC3=C1O)NCC4=CC=C(F)C=C4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (268 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang FH, et al. Discovery of novel 3-hydroxypicolinamides as selective inhibitors of HIV-1 integrase-LEDGF/p75 interaction. Eur J Med Chem. 2017 Jan 5;125:1051-1063. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

L-870810

All HIV Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

L-870810 Related Classifications

HY-12109 Related Classifications